"The pharmaceutical industry stands at an inflection point where data architecture decisions made today will determine whether organizations can deploy AI at scale or remain constrained by technical debt for another decade," says Sujit Murumkar, a visionary leader who designed and implemented enterprise scale modern data ecosystems for one of the largest pharmaceutical organization, describing the digital transformation facing life sciences companies worldwide.
For nearly two decades, enterprise data systems in life sciences have operated on infrastructure built for an earlier era of computing. Legacy platforms, designed primarily for transactional processing and static reporting, now strain under demands for real time analytics, machine learning model deployment, and integration of vast datasets spanning clinical research, genomics, commercial operations, and patient programs. The gap between what these systems deliver and what modern drug development requires has widened into a structural constraint that affects how quickly therapies reach patients.
